Chronic Pain News and Research

RSS

Single injection of morphine to fight persistent pain reduces testosterone level: Research

A single injection of morphine to fight persistent pain in male rats is able to strongly reduce the hormone testosterone in the brain and plasma, according to a new paper published in Molecular Pain.

4 Nov 2010

One-third of breast cancer survivors rate breast-conserving treatments as fair

A third of breast cancer survivors who received the breast-conserving treatments lumpectomy and radiation rate the appearance of their post-treatment breast as only "fair" or "poor" in comparison to their untreated breast, according to a new University of Pennsylvania School of Medicine study that will be presented today at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.

3 Nov 2010

FDA selects Rochester to lead initiative to identify improved pain treatments

Pain is the most common symptom leading patients to see a physician in the United States, yet the most widely prescribed medications - opioids and non-steroidal anti-inflammatory drugs (NSAIDS) - have major drawbacks, including the potential for misuse and abuse and adverse effects that limit long-term use. While scientists have made great strides in understanding the physical and chemical processes that occur when people feel pain, new treatments with improved safety and effectiveness are still needed for the more than 76 million Americans with acute and chronic pain.

2 Nov 2010

AAAOM, NCCAOM respond to report on cause of deaths due to improper acupuncture treatments

The American Association of Acupuncture and Oriental Medicine (AAAOM) and the National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM) are collaborating to respond to a recent report by British professor Edzard Ernst, published in The Guardian, claiming improperly trained acupuncture treatments have been the cause of deaths over the past 45 years.

2 Nov 2010

Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain

Labtec GmbH, Langenfeld, Germany announces the start of the phase II clinical development program for its sufentanil transdermal patch. The multicentric, randomized, open label study will evaluate efficacy and safety of Sufentanil TDS against standard treatment in patients with chronic cancer pain.

1 Nov 2010

Nanomedicine Center for Nucleoprotein Machines receives $16.1 million NIH award

The Georgia Tech-led Nanomedicine Center for Nucleoprotein Machines has received an award of $16.1 million for five years as part of its renewal by the National Institutes of Health (NIH). The eight-institution research team plans to pursue development of a clinically viable gene correction technology for single-gene disorders and demonstrate the technology's efficacy with sickle cell disease.

29 Oct 2010

Baxter to divest U.S. generic injectables business to Hikma

Baxter International Inc. announced today that it has entered into a definitive agreement to divest its U.S. generic injectables business to Hikma Pharmaceuticals PLC. The consideration for the divestiture arrangement totals approximately $112 million, subject to closing adjustments.

From Baxter International Inc. 29 Oct 2010

Physicians suggest tips to overcome acute pain

The truth is not all pain is created equal. Acute pain is where it all begins. Lasting for several months, acute pain is typically treated with rest, time and medication. For many, that is enough. But if the pain persists, it converts to chronic pain, and new methods must be explored.

29 Oct 2010

Pfizer announces approval of Lyrica capsules for peripheral neuropathic pain

Pfizer Inc announced that the Japanese Ministry of Health, Labour and Welfare approved Lyrica (pregabalin) capsules for the treatment of peripheral neuropathic pain. This follows the recent approval in Japan of Lyrica for the treatment of postherpetic neuralgia on April 16, 2010. Lyrica is the first medication approved for peripheral neuropathic pain in Japan where it is co-promoted with Eisai Co., Ltd.

29 Oct 2010

More effective therapeutic exercises underutilized in treatment of chronic neck pain

Duke University and University of North Carolina (UNC) researchers report in the November issue of Arthritis Care & Research that narcotics and diagnostic testing are overused in treating chronic neck pain. Their findings indicate clinicians may overlook more effective treatments for neck pain, such as therapeutic exercise. According to reviews cited in the study, evidence to support the effectiveness of therapeutic exercise in treating chronic neck pain is good, yet only 53% of subjects were prescribed such exercise.

28 Oct 2010

BDSI to initiate BEMA Buprenorphine Phase 3 program following positive End-of-Phase 2 meeting with FDA

BioDelivery Sciences International, Inc. today announced a positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) which took place on September 14, 2010. At that meeting, agreement was reached on the BEMA Buprenorphine development plan for the treatment of chronic pain.

28 Oct 2010

Cipher reports net revenue of $1.1 million for 2010 third quarter

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three and nine months ended September 30, 2010.

27 Oct 2010

Diamyd Medical to divide operations into two business areas

In her comments in today's year end report, Elisabeth Lindner, President and CEO of Diamyd Medical, states that the company has decided to divide its operations into two business areas beginning with the new 2010/2011 fiscal year; Diabetes and Pain.

22 Oct 2010

Researcher creates novel theory about chronic depression

Chronic depression is an adaptive, reparative neurobiological process gone wrong, say two University of California, San Diego School of Medicine researchers, positing in a new theory that the debilitating mental state originates from more ancient mechanisms used by the body to deal with physical injury, such as pain, tissue repair and convalescent behavior.

21 Oct 2010

Researchers to develop tailor-made pain management strategies for chronic pain

Research presented at this year's American Society of Anesthesiologists Annual Meeting offers new data in the quest to develop tailor-made pain management strategies based upon a patient's genetic predisposition and other important factors.

20 Oct 2010

$IOF urges health professionals and public to recognize signs of spinal fractures$

IOF urges health professionals and public to recognize signs of spinal fractures

A new report issued by the International Osteoporosis Foundation (IOF) for World Osteoporosis Day puts the spotlight on the severe impact of spinal fractures and calls on health professionals to recognize the signs of these fractures in their patients.

20 Oct 2010

Few legitimate opioid users are getting information to keep medications safe

For some people with ongoing or chronic pain, opioids (medications such as oxycodone or hydrocodone) can make the difference between disability and the ability to function at near-normal levels. For those with acute pain, such as pain after surgery or injury, sound pain management with opioids can speed healing and recovery.

19 Oct 2010

Positive results from Diamyd Medical's NP2 Enkephalin Phase I trial for chronic pain

Substantial and sustained reduction in pain scores were reported in the middle and high dose cohorts of Diamyd Medical's Phase I, open-label, dose escalation trial investigating NP2 Enkephalin as a potential therapy for chronic pain. No treatment related Serious Adverse Events have been observed in the study to date.

19 Oct 2010

IASP sponsors campaign for acute pain management

The Global Year Against Acute Pain launches today, focusing attention on a widely under-assessed and undertreated pain that affects most people throughout their lives. Sponsored by the International Association for the Study of Pain (IASP), the 12-month campaign focuses on education for health care professional and government leaders as well as public awareness to help lessen the gap between existing knowledge and technology for acute pain control and current pain management practice.

18 Oct 2010

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Nektar Therapeutics today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine.

18 Oct 2010